The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Aclaris Therapeutics Inc shares valued at $1,499,998 were purchased by Mehra Anand on Nov 19 ’24. At $2.25 per share, Mehra Anand acquired 666,666 shares. The insider’s holdings grew to 710,030 shares worth approximately $2.71 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Leonard Braden Michael purchased 206,025 shares, netting a total of over 256,357 in proceeds. Following the buying of shares at $1.24 each, the insider now holds 14,250,000 shares.
Before that, Leonard Braden Michael had added 167,544 shares to its account. In a trade valued at $216,400, the 10% Owner bought Aclaris Therapeutics Inc shares for $1.29 each. Upon closing the transaction, the insider’s holdings increased to 167,544 shares, worth approximately $53.65 million.
As published in a research note from Cantor Fitzgerald on November 20, 2024, Aclaris Therapeutics Inc [ACRS] has been rated up from a Neutral to an Overweight. Analysts at Leerink Partners upgraded the stock from ‘”a Market perform”‘ to ‘”an Outperform”‘ outlook in a report released in mid November. As of November 19, 2024, Jefferies has increased its “Hold” rating to a “Buy” for ACRS. Earlier on November 19, 2024, BTIG Research upgraded its rating. Their new recommendation was “a Buy” for ACRS stock which previously was a “a Neutral”.
Analyzing ACRS Stock Performance
During the last five days, there has been a drop of approximately -3.54%. Over the course of the year, Aclaris Therapeutics Inc shares have jumped approximately 263.81%. Shares of the company reached a 52-week high of $5.17 on 11/19/24 and a 52-week low of $0.86 on 01/12/24. A 50-day SMA is recorded $1.93, while a 200-day SMA reached $1.39. Nevertheless, trading volume fell to 0.83 million shares from 1.69 million shares the previous day.
Support And Resistance Levels for Aclaris Therapeutics Inc (ACRS)
According to the 24-hour chart, there is a support level at 3.66, which, if violated, would cause prices to drop to 3.50. In the upper region, resistance lies at 3.96. The next price resistance is at 4.10. RSI (Relative Strength Index) is 63.30 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.55, which suggests the price will decrease in the coming days. Percent R is at 42.99%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
